Key Kitty protects users from harm
CHARLOTTE, N.C. A new key fob is designed to protect women from potential attacks.
The Key Kitty — a ready-to-use self-defense weapon — is shaped like a cat’s head, with a flashlight button in the nose position, two holes where the eyes would be, and two sharp triangles for the cat’s ears. By putting two fingers through the eye holes, and carrying the cat’s head key fob in one’s hand (with the points facing outwards), the user can ward off attackers by hitting them with the Key Kitty’s sharp points.
The Key Kitty key fob provides:
- A flashlight to see a keyhole or steps at night;
- A retractable key or ID holder;
- A clasp to consistently hang keys in the same place in one’s purse;
- A quick-release clip; and
- A sharp object to deter an attacker if need be.
Swipe fee fix draws praise from industry groups
ARLINGTON, Va. Financial-reform legislation that seeks to regulate and curb interchange swipe fees that cause unforeseen expenses for retailers has drawn praise from industry groups.
The Food Marketing Institute on Friday applauded congressional efforts to overhaul interchange fees, which are collected by banks and credit card companies each time a consumer uses a credit or debit card to make a purchase, and ultimately can lead to higher prices for consumers. FMI has represented the voices of more than 26,000 supermarkets to address the outrageous fees and to negotiate reasonable swipe fees.
“FMI and our members have had interchange fee reform at the top of our list of priority issues for the past decade,” said Leslie G. Sarasin, FMI president and CEO. “These fees represent the fastest growing expense of our retail members and the only one over which we have zero control. This compromise is a good deal for consumers and is a strong step forward for competition. I feel confident that our customers have much to gain in the way of discounts and lower prices. We applaud the House and Senate conferees for their leadership.”
The National Retail Federation also praised the House-Senate conference committee’s decision to include a fix for rapidly rising debit card swipe fees.
“The conference committee has struck a blow for small retailers and their customers,” NRF SVP and general counsel Mallory Duncan said. “For years, these soaring fees have been taking billions of dollars out of consumers’ pockets and driving up prices. This is unsustainable. With this conference report in hand, Congress has an opportunity to stand up for Main Street businesses and consumers and rein in the greed of the big Wall Street banks and credit card companies.”
The National Community Pharmacists Association, which represents independent pharmacies, applauded the bipartisan legislation as well, saying it would protect consumers and small businesses from credit card companies’ use of exorbitant transaction fees and anti-competitive rules.
“If the bill becomes law, the constant spikes in fees for credit card transactions would be mitigated by regulations with real teeth in them. The legislation will hopefully result in reasonable transaction fees and restrict practices that threaten the financial viability of small businesses like independent community pharmacies, especially during these trying economic times,” NCPA president Joseph Harmison wrote in a letter.
BI: Linagliptin significantly lowers blood glucose levels
ORLANDO, Fla. An investigational treatment for Type 2 diabetes by Boehringer Ingelheim Pharmaceuticals significantly lowered blood sugar, according to results of a late-stage clinical study presented at a scientific meeting.
The drug maker announced Saturday the presentation of data from a phase 3 study of the once-daily pill linagliptin, saying that the drug achieved statistically significant and sustained reductions in blood sugar, according to standard measures. The results were presented at the 70th annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.
“It is imperative that blood sugar levels in people with Type 2 diabetes are adequately controlled,” Boehringer Ingelheim Pharmaceuticals executive director and medical leader for medical affairs in cardiovascular and metabolic medicine Giora Davidai said in a statement. “Uncontrolled blood sugar puts Type 2 diabetes patients at a higher risk of developing serious complications like renal impairment and cardiovascular disease, which are very common in patients with Type 2 diabetes.”